姚顺春, 张永川. lncRNA FEZF1-AS1和IGF2BP1在肝癌组织中的表达及临床意义[J]. 蚌埠医学院学报, 2023, 48(10): 1346-1350. DOI: 10.13898/j.cnki.issn.1000-2200.2023.10.004
    引用本文: 姚顺春, 张永川. lncRNA FEZF1-AS1和IGF2BP1在肝癌组织中的表达及临床意义[J]. 蚌埠医学院学报, 2023, 48(10): 1346-1350. DOI: 10.13898/j.cnki.issn.1000-2200.2023.10.004
    YAO Shun-chun, ZHANG Yong-chuan. Expression and clinical significance of lncRNA FEZF1-AS1 and IGF2BP1 in liver cancer[J]. Journal of Bengbu Medical College, 2023, 48(10): 1346-1350. DOI: 10.13898/j.cnki.issn.1000-2200.2023.10.004
    Citation: YAO Shun-chun, ZHANG Yong-chuan. Expression and clinical significance of lncRNA FEZF1-AS1 and IGF2BP1 in liver cancer[J]. Journal of Bengbu Medical College, 2023, 48(10): 1346-1350. DOI: 10.13898/j.cnki.issn.1000-2200.2023.10.004

    lncRNA FEZF1-AS1和IGF2BP1在肝癌组织中的表达及临床意义

    Expression and clinical significance of lncRNA FEZF1-AS1 and IGF2BP1 in liver cancer

    • 摘要:
      目的探讨长链非编码RNA(lncRNA)Fez家族锌指蛋白1反义RNA1(FEZF1-AS1)和胰岛素样生长因子2-mRNA结合蛋白1(IGF2BP1)在肝癌组织中的表达及临床意义。
      方法收集行手术治疗的60例原发性肝癌病人的肝癌组织和癌旁组织标本,采用实时荧光定量PCR(qRT-PCR)法检测肝癌组织、癌旁组织中lncRNA FEZF1-AS1、IGF2BP1 mRNA表达水平;免疫组织化学染色法检测肝癌组织、癌旁组织中IGF2BP1蛋白表达水平;分析肝癌组织lncRNA FEZF1-AS1、IGF2BP1表达水平与临床病理特征的关系;Kaplan-Meier生存分析肝癌组织lncRNA FEZF1-AS1、IGF2BP1表达与肝癌病人生存率的关系;Pearson分析肝癌组织lncRNA FEZF1-AS1与IGF2BP1 mRNA表达水平相关性。
      结果肝癌组织中lncRNA FEZF1-AS1、IGF2BP1 mRNA表达水平及IGF2BP1蛋白阳性表达率显著高于癌旁组织(P < 0.01);肝癌组织中lncRNA FEZF1-AS1与IGF2BP1 mRNA表达水平呈正相关(r=0.602,P < 0.01);不同年龄、性别、肿瘤大小、有无肝硬化、乙肝抗原阴阳性水平间lncRNA FEZF1-AS1、IGF2BP1表达差异无统计学意义(P>0.05),临床分期为Ⅲ~Ⅳ期、低中分化程度和有淋巴结转移的病人lncRNA FEZF1-AS1和IGF2BP1表达水平较高(P < 0.05);Kaplan-Meier生存分析显示,lncRNA FEZF1-AS1高表达组病人3年累积生存率显著低于lncRNA FEZF1-AS1低表达组(31.45% vs 61.40%,P < 0.01),IGF2BP1阳性表达组病人3年累积生存率显著低于IGF2BP1阴性表达组(31.18% vs 58.25%,P < 0.01)。
      结论肝癌组织中lncRNA FEZF1-AS1、IGF2BP1高表达,且二者表达与肝癌病人病理特征和预后有关,可能作为肝癌病人潜在的预后标志物。

       

      Abstract:
      ObjectiveTo investigate the expression and clinical significance of long non-coding RNA Fez family zinc finger protein 1 antisense RNA1 (lncRNA FEZF1-AS1) and insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) in liver cancer tissues.
      MethodsThe liver cancer tissue and para-cancerous tissue specimens were collected from 60 patients with primary liver cancer.The expression of lncRNA FEZF1-AS1 and IGF2BP1 at mRNA levels in liver cancer tissues and adjacent tissues was detected with real-time fluorescent quantitative PCR (qRT-PCR) method, the expression of IGF2BP1 at protein level was detected with immunohistochemical staining method, the relationship between the expression levels of lncRNA FEZF1-AS1 and IGF2BP1 in liver cancer tissues and the clinicopathological characteristics were analyzed, the relationship between the expressions of lncRNA FEZF1-AS1 and IGF2BP1 in liver cancer tissues and the survival rate of liver cancer patients were analyzed with Kaplan-Meier survival analysis, and the correlation between lncRNA FEZF1-AS1 and IGF2BP1 mRNA expression levels in liver cancer tissues was analyzed with Pearson method.
      ResultsThe expression of lncRNA FEZF1-AS1, IGF2BP1 at mRNA level and the positive expression rate of IGF2BP1 protein in liver cancer tissues were significantly higher than those in adjacent tissues (P < 0.01), and the expression of lncRNA FEZF1-AS1 and IGF2BP1 at mRNA level in liver cancer tissues were positively correlated (r=0.602, P < 0.01).There was no significant differences in the expressions of lncRNA FEZF1-AS1 and IGF2BP1 among different ages, genders, tumor sizes, cirrhosis or not, and hepatitis B antigen negative and positive levels (P>0.05).The expression levels of lncRNA FEZF1-AS1 and IGF2BP1 were higher in patients with clinical stage Ⅲ-Ⅳ, low and moderate differentiation and lymph node metastasis (P < 0.05).Kaplan-Meier survival analysis showed that the 3-year cumulative survival rate of patients in lncRNA FEZF1-AS1 high expression group was significantly lower than that in lncRNA FEZF1-AS1 low expression group (31.45% vs 61.40%, P < 0.01), the 3-year cumulative survival rate of patients in IGF2BP1 positive expression group was significantly lower than that in IGF2BP1 negative expression group (31.18% vs 58.25%, P < 0.01).
      ConclusionsLncRNA FEZF1-AS1 and IGF2BP1 are highly expressed in liver cancer tissues, and their expressions are related to the pathological characteristics and prognosis of liver cancer patients, which may serve as potential prognostic markers for liver cancer patients.

       

    /

    返回文章
    返回